All In Biotech

NDA 019079 · Harrow Eye

Flarex

Fluorometholone Acetate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Feb 11, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

31

5 Phase 3, 1 recruiting

FAERS reports

267

102 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2025.

INDICATIONS AND USAGE FLAREX (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 11, 1986 Original approval · Type 2 - New Active Ingredient
1 products under this application
  • FLAREX · FLUOROMETHOLONE ACETATE 0.1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorometholone" as an intervention, any sponsor and status, largest first.

All 31 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain64
  • eye irritation30
  • drug ineffective22
  • vision blurred21
  • headache19
  • off label use19
  • product dose omission issue19
  • ocular hyperaemia18
  • photophobia16
  • fatigue15
  • dizziness12
  • diarrhoea11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
200610
20083
20105
20113
20123
20132
20146
20154
201612
20179
201812
20199
202018
202123
202231
202358
202429
202519
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Flarex (Fluorometholone Acetate)

2024 spending

$2.6M

Beneficiaries

10,380

19,312 claims

Per beneficiary

$254

$24.71 per unit

View as table
YearSpending
2020$1,196,373
2021$2,229,802
2022$3,567,406
2023$4,002,192
2024$2,638,669

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 96 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.